Novel Hemostatic Agents: A Focus on Recombinant Factor VIIa and Factor XIII
نویسندگان
چکیده
منابع مشابه
Recombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient
INTRODUCTION Recombinant factor VIIa (rFVIIa; NovoSeven) is well recognized as an effective hemostatic agent in the management and prophylaxis of patients with hemophilia. We report here the successful use of rFVIIa in a coagulopathic burn patient. METHODS A 63-year-old man was admitted with significant upper-body burns in a total body surface area of 60%. Initial management included early in...
متن کاملRecombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
Congenital factor XIII (FXIII) deficiency is a rare, autosomal-recessive disorder, with most patients having an A-subunit (FXIII-A) deficiency. Patients experience life-threatening bleeds, impaired wound healing, and spontaneous abortions. In many countries, only plasma or cryoprecipitate treatments are available, but these carry a risk for allergic reactions and infection with blood-borne path...
متن کاملRecombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
2015 Factor XIII (FXIII) is composed of two catalytic A subunits and two carrier B subunits. Following activation by thrombin FXIII becomes plasma transglutaminase, which crosslinks the γ-glutamyl-ɛ-lysine residues of fibrin chains stabilizing fibrin clot. Congenital deficiency of factor XIII results in a severe life-long hemorrhagic disorder, abnormal wound healing in about 30% of patients and...
متن کاملRecombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conducte...
متن کاملChallenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
Recombinant factor VIIa (rFVIIa) was developed in the early 1990s to provide "bypassing" hemostatic therapy for hemophilia A and B patients with inhibitors. More recently, it has been licensed for use in patients with inherited deficiency of factor VII. Since it was licensed for use in hemophilia with inhibitors in the US, Europe, and other countries for these specific indications, it has been ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transfusion Alternatives in Transfusion Medicine
سال: 2004
ISSN: 1295-9022,1778-428X
DOI: 10.1111/j.1778-428x.2004.tb00116.x